Zoetis’ stock price has fluctuated over the past year, with a current closing price of $146.76 USD, and valuation ratios indicating a price-to-earnings ratio of 26.89 and price-to-book ratio of 13.82.
Zoetis A shares have reached a 52-week high of $200.33 USD, driven by investor confidence in the company’s strong financial performance and future prospects.
Zoetis A shares have experienced significant market volatility, with a 52-week high of $200.33 and low of $144.80, and a current closing price of $164.43.
Syngene International has made a significant move in the biotech industry by acquiring a state-of-the-art biologics manufacturing facility in Baltimore, positioning the company for success in the lucrative biologics market.
Zoetis A has delivered a remarkable 280% return on investment over the past decade, cementing its position as a market leader with a market value of nearly $78 billion.